185 related articles for article (PubMed ID: 12434296)
1. Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2.
Fedier A; Ruefenacht UB; Schwarz VA; Haller U; Fink D
Br J Cancer; 2002 Oct; 87(9):1027-33. PubMed ID: 12434296
[TBL] [Abstract][Full Text] [Related]
2. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites.
Fedier A; Schlamminger M; Schwarz VA; Haller U; Howell SB; Fink D
Ann Oncol; 2003 Jun; 14(6):938-45. PubMed ID: 12796033
[TBL] [Abstract][Full Text] [Related]
3. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
Fedier A; Steiner RA; Schwarz VA; Lenherr L; Haller U; Fink D
Int J Oncol; 2003 May; 22(5):1169-73. PubMed ID: 12684687
[TBL] [Abstract][Full Text] [Related]
4. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
5. Multiple mutations are common at mouse Aprt in genotoxin-exposed mismatch repair deficient cells.
Shin CY; Mellon I; Turker MS
Oncogene; 2002 Mar; 21(11):1768-76. PubMed ID: 11896608
[TBL] [Abstract][Full Text] [Related]
6. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells.
Perego P; Gatti L; Caserini C; Supino R; Colangelo D; Leone R; Spinelli S; Farrell N; Zunino F
J Inorg Biochem; 1999 Oct; 77(1-2):59-64. PubMed ID: 10626355
[TBL] [Abstract][Full Text] [Related]
7. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
8. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
9. Brostallicin (PNU-166196)--a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells.
Fedier A; Fowst C; Tursi J; Geroni C; Haller U; Marchini S; Fink D
Br J Cancer; 2003 Oct; 89(8):1559-65. PubMed ID: 14562032
[TBL] [Abstract][Full Text] [Related]
10. Ionizing radiation-induced apoptosis via separate Pms2- and p53-dependent pathways.
Zeng M; Narayanan L; Xu XS; Prolla TA; Liskay RM; Glazer PM
Cancer Res; 2000 Sep; 60(17):4889-93. PubMed ID: 10987303
[TBL] [Abstract][Full Text] [Related]
11. Levels of H-ras codon 61 CAA to AAA mutation: response to 4-ABP-treatment and Pms2-deficiency.
Parsons BL; Delongchamp RR; Beland FA; Heflich RH
Mutagenesis; 2006 Jan; 21(1):29-34. PubMed ID: 16314341
[TBL] [Abstract][Full Text] [Related]
12. Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair.
Mohd AB; Palama B; Nelson SE; Tomer G; Nguyen M; Huo X; Buermeyer AB
DNA Repair (Amst); 2006 Mar; 5(3):347-61. PubMed ID: 16338176
[TBL] [Abstract][Full Text] [Related]
13. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity and point mutation at Aprt locus in T cells and fibroblasts of Pms2-/- mice.
Shao C; Yin M; Deng L; Stambrook PJ; Doetschman T; Tischfield JA
Oncogene; 2002 Apr; 21(18):2840-5. PubMed ID: 11973643
[TBL] [Abstract][Full Text] [Related]
15. p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase.
Fedier A; Moawad A; Haller U; Fink D
Int J Oncol; 2003 Nov; 23(5):1431-7. PubMed ID: 14532987
[TBL] [Abstract][Full Text] [Related]
16. Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Fedier A; Schwarz VA; Walt H; Carpini RD; Haller U; Fink D
Int J Cancer; 2001 Aug; 93(4):571-6. PubMed ID: 11477562
[TBL] [Abstract][Full Text] [Related]
17. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse.
Chen PC; Dudley S; Hagen W; Dizon D; Paxton L; Reichow D; Yoon SR; Yang K; Arnheim N; Liskay RM; Lipkin SM
Cancer Res; 2005 Oct; 65(19):8662-70. PubMed ID: 16204034
[TBL] [Abstract][Full Text] [Related]
18. Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements.
Chen J; Sadowski I
Proc Natl Acad Sci U S A; 2005 Mar; 102(13):4813-8. PubMed ID: 15781865
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair.
Manic S; Gatti L; Carenini N; Fumagalli G; Zunino F; Perego P
Curr Cancer Drug Targets; 2003 Feb; 3(1):21-9. PubMed ID: 12570658
[TBL] [Abstract][Full Text] [Related]
20. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
